Alector, Inc. (NASDAQ:ALEC) Short Interest Update

01 Jan 2026, 06:16 by Tristan Rich · The Markets Daily

Alector, Inc. (NASDAQ:ALEC – Get Free Report) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 6,319,929 shares, a growth of 35.9% from the November 30th total of 4,651,197 shares. Currently, 6.4% of the shares of the company are sold short. Based on an average daily volume of 1,976,117 shares, the short-interest ratio is presently 3.2 days. Based on an average daily volume of 1,976,117 shares, the short-interest ratio is presently 3.2 days. Currently, 6.4% of the shares of the company are sold short.

Insider Activity

In other news, CFO Neil Lindsay Berkley sold 37,261 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total value of $41,732.32. Following the sale, the chief financial officer directly owned 374,309 shares of the company’s stock, valued at approximately $419,226.08. This represents a 9.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sara Kenkare-Mitra sold 41,687 shares of Alector stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $1.12, for a total value of $46,689.44. Following the transaction, the insider owned 501,652 shares of the company’s stock, valued at $561,850.24. The trade was a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 196,104 shares of company stock valued at $220,064. 9.70% of the stock is owned by company insiders.

Institutional Trading of Alector

A number of institutional investors have recently bought and sold shares of the business. Invesco Ltd. increased its holdings in shares of Alector by 209.6% during the first quarter. Invesco Ltd. now owns 148,576 shares of the company’s stock worth $183,000 after purchasing an additional 100,591 shares during the period. Nuveen LLC bought a new stake in shares of Alector in the first quarter valued at approximately $170,000. Walleye Capital LLC grew its position in Alector by 108.3% during the first quarter. Walleye Capital LLC now owns 305,601 shares of the company’s stock worth $376,000 after buying an additional 158,922 shares in the last quarter. Ieq Capital LLC acquired a new stake in Alector during the first quarter worth approximately $99,000. Finally, State of Wyoming bought a new position in Alector during the 1st quarter worth $242,000. Institutional investors own 85.83% of the company’s stock.

Alector Stock Performance

Shares of NASDAQ ALEC opened at $1.56 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.76 and a quick ratio of 3.76. The firm has a market cap of $170.27 million, a price-to-earnings ratio of -1.46 and a beta of 0.67. The stock’s fifty day moving average price is $1.36 and its two-hundred day moving average price is $1.94. Alector has a one year low of $0.87 and a one year high of $3.40.

Alector (NASDAQ:ALEC – Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. Alector had a negative return on equity of 123.02% and a negative net margin of 156.03%.The company had revenue of $3.26 million during the quarter, compared to the consensus estimate of $3.49 million. On average, equities analysts forecast that Alector will post -1.88 EPS for the current year.

Analyst Ratings Changes

ALEC has been the topic of a number of recent analyst reports. Cowen lowered Alector to a “hold” rating in a report on Wednesday, October 22nd. Cantor Fitzgerald downgraded Alector from an “overweight” rating to a “neutral” rating in a report on Wednesday, October 22nd. HC Wainwright reduced their price objective on shares of Alector from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Mizuho set a $1.50 price objective on shares of Alector and gave the company a “neutral” rating in a report on Wednesday, October 22nd. Finally, BTIG Research cut shares of Alector from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $3.25.

Get Our Latest Report on Alector

Alector Company Profile

(Get Free Report)

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.